Gene-therapy companies got a boost during Monday trading after Novartis AG's (NVS) $8.7 billion deal to buy AveXis Inc. (AVXS), making good on CEO Vasant Narasimhan's promise to strike deals to refocus the company. Analysts at Chardan said Regenxbio Inc. (RGNX), Spark Therapeutics Inc. (ONCE) and Nightstar Therapeutics PLC (NITE) could be among the company's next targets. Regenxbio shares jumped 22% to $33.05 during Monday trading, while Spark shares rose 14% to $70.75 and rand Nightstar rose 8.1% to $12.65. (imani.moise@wsj.com; @moisenoise)

(END) Dow Jones Newswires

April 09, 2018 12:44 ET (16:44 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
AVEXIS, INC. (NASDAQ:AVXS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos AVEXIS, INC..
AVEXIS, INC. (NASDAQ:AVXS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos AVEXIS, INC..